Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
SUMMARY Cancers arising in mucosal tissues account for a disproportionately large fraction of malignancies. IgG and the neonatal Fc receptor for IgG (FcRn) have an important function in the mucosal immune system which we have now shown extends to the induction of CD8+ T cell-mediated anti-tumor immunity. We demonstrate that FcRn within dendritic cells (DC) was critical for homeostatic activation of mucosal CD8+ T cells which drove protection against the development of colorectal cancers and lung metastases. FcRn-mediated tumor protection was driven by DC activation of endogenous tumor-reactive CD8+ T cells via the cross-presentation of IgG complexed antigens (IgG IC) as well as the induction of cytotoxicity-promoting cytokine secretion, particularly interleukin-12 (IL-12), both of which were independently triggered by the FcRn–IgG IC interaction in murine and human DC. FcRn thus has a primary role within mucosal tissues in activating local immune responses that are critical for priming efficient anti-tumor immunosurveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 5×
“An important prerequisite for FcRn-mediated tumor protection is the presence of IgG capable of recognizing a tumor antigen and initiating a cascade of FcRn-dependent anti-tumor responses that will feed in to the recently described ‘‘Cancer-Immunity Cycle’’ (Brichory et al., 2001; Chen and Mellman, 2013; Desmetz et al.…”
InfluentialIntestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 4×
“It is well accepted that cytotoxic CD8+ T cell-mediated responses are critical for efficient anti-tumor immunity (Pages et al., 2005) and FcRn has recently been shown to enable highly efficient cross-presentation of IgG-complexed antigens by CD8−CD11b+ DC (Baker et al., 2011).”
InfluentialChemically induced mouse models of intestinal inflammation
Wirtz, S., Neufert, C., Weigmann, B., & Neurath, M. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.41 · Cited by 1,567
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 2×
“…from WT donors, but not from Fcgrt−/− donors, into Fcgrt−/− recipients decreased tumor frequency and total neoplastic colon surface area (tumor load) (Grivennikov et al., 2012) to quantities similar to those observed in WT mice and significantly less than seen in PBS treated Fcgrt−/− animals…”
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., & Ward, E. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810796106 · Cited by 211 · cited 5×
“Sally Ward (University of Texas Southwestern Medical Center) (Montoyo et al., 2009).”
InfluentialClaypool, S. M., Dickinson, B. L., Wagner, J. S., Johansen, F.-E., Venu, N., Borawski, J. A., Lencer, W. I., & Blumberg, R. S. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0832 · Cited by 139
Self-citation
Cited by
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Self-citationNeonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
“Earlier studies have demonstrated that crosslinking of FcRn by multivalent immune complexes can result in both increased lysosomal trafficking of FcRn-ligand complexes and immune activation (33, 34), and further studies are necessary to determine how affinity and/or valency of the FcRn-inhibitor complex affects intrac…”
BackgroundEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Self-citationSand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Pyzik, M., Rath, T., Lencer, W. I., Baker, K., & Blumberg, R. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403014 · Cited by 298
Self-citationThe therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Self-citationYue, Y., Xu, J., Li, Y., Cheng, K., Feng, Q., Ma, X., Ma, N., Zhang, T., Wang, X., Zhao, X., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00886-2 · Cited by 264
Distribution of FcRn Across Species and Tissues
Latvala, S., Jacobsen, B., Otteneder, M. B., Herrmann, A., & Kronenberg, S. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417705095 · Cited by 178
Smith, B., Kiessling, A., Lledo-Garcia, R., Dixon, K. L., Christodoulou, L., Catley, M. C., Atherfold, P., D’Hooghe, L. E., Finney, H., Greenslade, K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1505464 · Cited by 117
“Although Baker et al.(60) reported that in dendritic cells, interaction between FcRn and immune complexes can lead to secretion of IL-12, to our knowledge there is no mention in the literature of cellular signalling that occurs as a result of FcRn binding its natural ligands, IgG or albumin.”
BackgroundNeonatal Fc receptor – biology and therapeutics
Bussel, J. B., Cines, D. B., & Blumberg, R. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2312718 · Cited by 49
Self-citationDeveloping the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor
Rossini, S., Noé, R., Daventure, V., Lecerf, M., Justesen, S., & Dimitrov, J. D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000732 · Cited by 14
Metadata
- Authors
- Baker, K., Rath, T., Flak, M. B., Arthur, J. C., Chen, Z., Glickman, J. N., Zlobec, I., Karamitopoulou, E., Stachler, M. D., Odze, R. D., Lencer, W. I., Jobin, C., & Blumberg, R. S.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 39
- Issue
- 6
- Pages
- 1095-1107
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2091734007
- Cited by
- 141
- References
- 10
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.